Tag Archives: Hepatitis

Two BC based Clinical Trials Examined at the Liver Meeting

Two BC based Clinical Trials Examined at the Liver MeetingThis post examines two BC based clinical trials BC for hep C treatments that were presented at the Liver Meeting 2016 earlier this month.

Clinical Trial Abstract #60 – Impact of drug use and opioid substitution therapy on hepatitis C reinfection: The BC Hepatitis Testers Cohort by Nazrul Islam, et al.

Summary: This clinical trial identified the risk factors that may lead to hep C reinfection by looking at those tested for the virus in BC between 1990-2013. It looked at data about their medical visits, hospitalizations, and prescription drugs.  Those who were able to clear the virus on their own were included in this study. The study’s results showed that 11.8% of those who cleared the virus on their own were reinfected within the study’s 19 year time period. This rate was higher in this group than in those who had cleared the virus through treatment. However, this group also had a higher proportion of people who recently injected drugs. Using injected drugs made the risk of reinfection higher, where as, using opioid substitution therapy (OST) reduced the hep C reinfection risk. Also, being younger was seen to increase one’s of reinfection risk, as well as, being co-infected with HIV.  Whereas, being female and being infected with hep B lowered one’s chances of reinfection. From these findings, the study concluded that treatment should be combined with harm reduction programs.

Clinical Trial Abstract #175 – The impact of sustained virological response to HCV infection on long term risk of hepatocellular carcinoma: The BC Hepatitis Testers Cohort by Naveed Z. Janjua, et al.

Summary: The risk of hepatocellular carcinoma (HCC), the most common type of liver cancer, after being cured of hep C in North America hasn’t been looked at in depth. This study assessed the effect of sustained virologic response (hep C cure) on the risk of HCC among a large Canadian population base, by examining the same patient database as the above clinical trial. RESULTS: It found that the risk of HCC was higher in those who weren’t cured than those who were (1.1/1000 person-yr(PY) in the SVR group and 7.2/1000 PY in the no-SVR group). It found that the risk of developing HCC was higher in those with liver cirrhosis, who were older, male, had hep C genotype 3 vs 1, and drank alcohol. The HCC incidence post treatment increase was steeper in the no-SVR vs the SVR group, but that SVR (cure) doesn’t eliminate the risk of HCC.

 The Liver Meeting 2016

The Liver Meeting 2016, the American Association for the Study of Liver Diseases (AASLD)‘s 67th annual meeting, was held November 11th – 15th. Last year’s meeting drew more than 9,500 international hepatologists and hepatology health professionals to San Francisco to discuss the latest treatments and research for liver diseases. This year, Boston, Massachusetts, hosted the meeting and, as always, it was exciting.

More information about The Liver Meeting 2016 or these and other studies can be found in our blog post The Liver Meeting 2016 Hep C Abstract Highlights (Part2) or on the American Association for the Study of Liver Diseases (AASLD)’s website.

World Hepatitis Summit Presentation Slides and Thoughts

World Hepatitis Summit Presentation SlidesWorld Hepatitis Summit presentation slides have just been released online. Topics around hep C treatment range from Treatment and access to drugs to The funding of viral hepatitis to Prevention.

Daryl Luster’s Quote about the World Hepatitis Summit 2015

“The recent World Hepatitis Summit in Scotland gathered people from around the globe; people who are involved in all levels of civil society, governments, science, and medical fields. We were well represented with a strong Canadian delegate presence from across the country.

The take-away message for me and other colleagues attending was that as much as we differ from country to country, we have far more in common in the barriers we face and in the work that we do to address hepatitis C as an important health concern.” –Daryl Luster, PHCN’s president and a member of Action Hepatitis Canada‘s executive, attended the World Hepatitis Summit as a representative for Action Hepatitis Canada (AHC).

World Hepatitis Summit 2015

The World Hepatitis Summit 2015 took place in Glasgow, Scotland, September 2 – 4. Jointly hosted by the World Health Organization (WHO) and the World Hepatitis Alliance (WHA), as well as the Scottish Government, the summit gathered over 600 policy makers, patients, and other key stakeholders, from over 90 countries, in Glasgow to garner political and financial commitments required to tackle hepatitis.

Last year, at the Sixty-seventh World Health Assembly, countries from around the world committed to addressing hepatitis by implementing national strategies. They called upon WHO to create a global hepatitis target setting and monitoring system.

This year, the World Hepatitis Summit supported this initiative by creating a space where strategies and best practices could be shared.

World Hepatitis Summit 2015

World Hepatitis Summit 2015

The World Hepatitis Summit 2015 (#Hepatitis2015) in Glasgow, Scotland, is set to take place September 2 – 4 and PHCN is pleased to announce that our president, Daryl Luster, will be there.

The World Hepatitis Summit 2015 is the first conference of its kind to directly address the global burden of viral hepatitis. Jointly hosted by the World Health Organization (WHO) and the World Hepatitis Alliance (WHA), as well as the Scottish Government, the summit will gather policy makers, patients, and other key stakeholders in Glasgow to garner political and financial commitments required to tackle hepatitis.

Last year, at the Sixty-seventh World Health Assembly, countries from around the world committed to addressing hepatitis by implementing national strategies. They called upon WHO to create a global hepatitis target setting and monitoring system.

This year, the World Hepatitis Summit will support this initiative by creating a space where strategies and best practices can be shared. The summit will provide the opportunity for governments to learn about WHO’s Global Hepatitis Programme and the progress that has been made towards a target setting and monitoring system. In addition, WHO will present its new toolkit to assist governments in the development and implementation of efforts against hepatitis.

Furthermore, the World Hepatitis Summit 2015 will strive for action and commitment from global funders, the pharmaceutical industry, and other important groups to “make real lasting progress in drastically reducing the burden of viral hepatitis.”

Daryl Luster, PHCN’s president and a member of Action Hepatitis Canada‘s executive, is attending the World Hepatitis Summit as a representative for Action Hepatitis Canada (AHC). In his AHC role, Daryl will present about Action Hepatitis Canada and World Hepatitis Day.

Daryl will also host and present at Action Hepatitis Canada’s luncheon for Canadian summit delegates. During the summit, this luncheon will give Canadian delegates an opportunity to discuss advocacy and ways that Canadian hepatitis advocates can support each other and work together towards improving Canada’s response to hepatitis.

Daryl has also been invited to take part in a consultation hosted by the Medicines Patent Pool. The Medicines Patent Pool is a United Nations-backed organization that aims to lower the prices of HIV medicines and facilitate the development of better-adapted HIV medicines through voluntary licensing and patent pooling. The organization is currently studying the feasibility of expanding its work into the field of hepatitis C and seeking the views of people living with hep C, NGOs, and others.

PHCN wishes Daryl and all of the World Hepatitis Summit 2015 delegates luck as they prepare to meet next week.

“The global burden of viral hepatitis can be overcome only when the world is united in action.” –Charles Gore, WHA President

World Hepatitis Summit

PharmaCare Drug Coverage Review for Holkira Pak

Holkira PakThe Hepatitis C Treatment Information Project received an advance notification from BC’s Ministry of Health that Holkira Pak (generic name: ombitasvir/paritaprevir/ritonavir and dasabuvir) will soon be considered for PharmaCare coverage. The tentative dates for input into this process are from Wednesday, April 22nd, to Wednesday, May 20th.

If you are a BC resident and answer yes to any of the following questions for Holkira Pak, you can give your input:

  1. Do you have hep C?
  2. Are you a caregiver to someone who has hep C?
  3. Does your patient group represent patients who have hep C AND have you registered with PharmaCare to give input?  (Learn more about registering your organization).

Please note that PharmaCare’s questionnaire for Holkira Pak may not be available for another couple of weeks.

For more information, please contact  Your Voice or the Hepatitis C Treatment Information Project.